Navigation Links
Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
Date:3/29/2011

SAN DIEGO, March 29, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that an abstract highlighting the Company's mitochondrial inhibitor program has been accepted for a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 4, 2011 at 1:00 p.m. EDT at the Orange County Convention Center in Orlando.

Ayesha Alvero, M.D., Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine, will present new laboratory data demonstrating the ability of NV-128, Marshall Edwards' first-generation investigational compound, to significantly depress mitochondrial function and induce cell death in chemotherapy-resistant ovarian cancer stem cells.  This cell death results from the activation of two independent pathways: 1) AMP kinase leading to the inhibition of mTOR1 and mTOR2 and the induction of autophagy; and 2) mitochondrial MEK/ERK leading to mitochondrial depolarization. These data suggest that the simultaneous activation of these pathways appears to be a potent stimulus to induce cell death in a chemo-resistant ovarian cancer stem cell population identified by researchers at Yale University.

A copy of the poster, entitled "Depression of Mitochondrial Bioenergetics is a Potent Death Stimulus in the Ovarian Cancer Stem Cells," will be available immediately following Dr. Alvero's presentation at www.marshalledwardsinc.com.

Marshall Edwards has identified a next-generation compound called NV-344 that has demonstrated significantly more activity than NV-128 across a broad range of tumor cells in pre-clinical studies. The Company is in the process of completing drug manufacturing of NV-344
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novogen and Marshall Edwards Sign Asset Purchase Agreement
2. Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
3. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
4. Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF
5. Protege of Nobel Prize Winner Robert Edwards Carries on his IVF Legacy
6. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
7. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
8. Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
9. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
10. Reportlinker Adds Quantum Dots: Technologies and Global Markets
11. Neogen Reports 27% Increase in Quarterly Net Income
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... Aug. 21, 2014 Telomere Biosciences, LLC ... Nutraceutical "TELO-20 for Dogs" with Telomerase Activation ... in the world for dogs. Telomeres are the ... in the body. A wealth of ground-breaking research ... Telomere Science and Aging, including Nobel laureates, has ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
(Date:8/21/2014)... 2014 OTC Markets Group Inc. ... biotechnology company, on its approval to list on ... OTCQX®, the best marketplace for established U.S. and ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... of its growth strategy and achievement of this ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... PARIS, France - 11 June 2008 Findings from ... every four-week subcutaneous injections of golimumab (CNTO 148) 50 ... significant improvements in the signs and symptoms of rheumatoid ... disease activity, with some patients achieving remission as measured ...
... DRRX ) announced today that a New ... submitted to the U.S. Food,and Drug Administration (FDA). ... formulation of oxycodone intended to treat moderate to ... designed to resist,common methods of prescription drug misuse ...
... Research Program Awards Peer-Reviewed Grant, SARASOTA, Fla., June ... awarded the Florida Department of Health and James &,Esther ... its advanced cancer research in using B-amyloid protein to ... the amount of $100,000 was awarded to Roskamp,s,Investigator Daniel ...
Cached Biology Technology:Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 2Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 3Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Roskamp Institute Wins Grant for Lung Cancer Research 2
(Date:8/20/2014)... 2014 George E. Fox, a John and Rebecca Moores ... (UH), was named a fellow in the International Society for ... Fox is one of four members two from the ... as fellows in 2014. Fellows are elected every three years, ... 500 members from more than 20 countries, the ISSOL includes ...
(Date:8/20/2014)... research finds life can persist in a cold, dark ... a team that examined waters and sediments from a ... found the extreme environment supports microbial ecosystems. , ... her colleagues has implications for life in other extreme ... The findings are published in the current edition of ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... in German . The climate after ... was cool, later very warm and then cool again. Thanks ... as paleontologists from the University of Zurich have reconstructed. The ... atmosphere, initially gave rise to new, short-lived species. In the ...
... . , Day after day, legions of microorganisms ... from Bielefeld University,s Center for Biotechnology (CeBiTec) are taking a ... job. They are analysing the entire genetic information of the ... From the beginning of 2013, the Californian Joint Genome Institute ...
... published online in Cell reports the latest ... sequencing in autism patients. This study provides a global ... on genetic diversity and susceptibility in autism, and its ... collaborative effort led by international teams comprised of the ...
Cached Biology News:Ups and downs of biodiversity after mass extinction 2A giant puzzle with billions of pieces 2A giant puzzle with billions of pieces 3The findings between DNMs and autism provides global view of mutability on human diseases 2
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: